Why did Cipla (CIPLA) stock move recently?

On 8/25/2026, Cipla moved -1.1% — Cipla closed at Rs 1,422, down on profit booking, bucking an otherwise firm pharma and healthcare sector that led Nifty gains for the session. It was among the day's notable Nifty losers. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Cipla (CIPLA) overvalued or fairly valued?

MarketChacha shows Cipla's valuation in context — a forward P/E of about 21.4, a price-to-book of about 3.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Cipla's revenue?

Cipla reported revenue of ₹18,980 Cr for FY2026, with net profit of ₹3,515 Cr, per official filings.

What is the share price of Cipla (CIPLA)?

Cipla last traded at ₹1,376.30 (+1.9% on the day), as of 9/17/2026 — a delayed quote shown for education, not investment advice.

Cipla

CIPLA · NSE · Pharma · India

Snapshot

TickerCIPLA

ExchangeNSE

SectorPharma

IndustryDrug Manufacturers - Specialty & Generic

CountryIndia

Employees31,369

HeadquartersMumbai, India

Websitewww.cipla.com

Filings tracked22

About Cipla

Cipla Limited, together with its subsidiaries, manufactures, develops, sells, and distributes pharmaceutical products in India, the United States, South Africa, and internationally. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney disorders, alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Who owns it

Promoters31.1%
Institutions44.3%
Public & other24.6%

232 institutional holders

Ownership breakdown from public market data. Promoter pledge is not included here — that comes from exchange shareholding filings.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Net margin trend12.3% → 13.8%

Margin has expanded by about 1.5 points — the business is getting more profitable.

Growth qualityrev 5% · PAT 8%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (Yahoo Finance). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev ₹8,018 Cr · EPS 13.54

Est. earnings growth +23.7%

Next fiscal year

Rev ₹34,730 Cr · EPS 63.47

Est. earnings growth +25.0%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: Yahoo Finance

Annual

Quarterly · last 5

Revenue (FY2026)

₹28,163 Cr

Net margin

13.8%

Revenue CAGR (3y)

+7.4%

Profit CAGR (3y)

+11.5%

Net profit (FY2026)

₹3,879 Cr

Ask MarketChacha about CIPLA

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 25, 2026
Cipla closed at Rs 1,422, down on profit booking, bucking an otherwise firm pharma and healthcare sector that led Nifty gains for the session. It was among the day's notable Nifty losers.
source 1 ↗source 2 ↗· confidence: medium
Jun 22, 2026
Cipla shares rose over 4% after Citi maintained its Buy rating and placed the stock on a 90-day Positive Catalyst Watch, highlighting multiple upcoming growth triggers.
source 1 ↗source 2 ↗· confidence: high

Daily moves with the verified reason behind them. Education only — not investment advice.

On MarketChacha

Posts about CIPLA

Financials

Yearly

Period	Revenue	Net profit	Net margin
FY2026	₹28,163 Cr	₹3,879 Cr	13.8%
FY2025	₹27,548 Cr	₹5,273 Cr	19.1%
FY2024	₹25,774 Cr	₹4,122 Cr	16.0%
FY2023	₹22,753 Cr	₹2,802 Cr	12.3%

Quarterly

Period	Revenue	Net profit	Net margin
Q1 FY27	₹7,119 Cr	₹789 Cr	11.1%
Q4 FY26	₹6,541 Cr	₹555 Cr	8.5%
Q3 FY26	₹7,074 Cr	₹676 Cr	9.6%
Q2 FY26	₹7,589 Cr	₹1,351 Cr	17.8%
Q1 FY26	₹6,957 Cr	₹1,298 Cr	18.7%

Figures as reported, in ₹ (crore). Source: Yahoo Finance.

Filings & announcements

2026

Press Release / Media Release
Please find enclosed press release titled ''Cipla Announces Exclusive Partnership with Qilu Pharmaceutical for the Licensing and Supply of Biosimilar to Keytruda (Pembrolizumab) in the US''
BSE9/3/2026
Update On USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA
Please find enclosed disclosure.
BSE8/28/2026
Restructuring
Please find enclosed disclosure.
BSE8/27/2026
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find attached disclosure on ESG Ratings.
BSE8/11/2026
Update On USFDA Inspection At Invagen Manufacturing Facility In Hauppauge, Long Island, New York, USA
Please find enclosed intimation.
BSE8/4/2026
Allotment of ESOP / ESPS
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirments) Regulations, 2015, we hereby notify that the Operations and Administrative Committee ....
BSE7/31/2026
Cipla Receives U.S. FDA Approval For Generic Advair Diskus®
Please find enclosed disclosure
BSE7/27/2026
Earnings Call Transcript
Please find enclosed Earnings Call Transcript - Q1FY27
BSE7/27/2026
Intimation Under Regulation 30(5) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed disclosure
BSE7/23/2026
Grant Of Stock Option And Employee Stock Appreciation Rights
Please find enclosed disclosure
BSE7/23/2026
Change in Management
Please find enclosed the disclosure relating to the change in SMP.
BSE7/23/2026
Change in Management
Please find enclosed the disclosure relating to the change in CFO.
BSE7/23/2026
Board Meeting Outcome for Outcome Of Board Meeting Dated 23Rd July 2026
Please find enclosed outcome of Board meeting.
BSE7/23/2026
USFDA Inspection At Invagen Manufacturing Facility In Central Islip, Long Island, NY, USA
Please find enclosed disclosure on USFDA inspection at InvaGen manufacturing facility in Long Island, NY, USA
BSE7/18/2026
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find enclosed disclosure on ESG Rating.
BSE7/12/2026
Corrigendum To The Intimation Dated 3Rd July, 2026 Regarding 'Transcript Of The 90Th Annual General Meeting'
Please find enclosed transcript.
BSE7/4/2026
Transcript Of The 90Th Annual General Meeting
Please find enclosed transcript.
BSE7/3/2026
Appointment of Statutory Auditor/s
Please find enclosed intimation
BSE6/25/2026
Shareholder Meeting / Postal Ballot-Outcome of AGM
Please find enclosed Proceedings of AGM
BSE6/25/2026material
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report
Details of voting results of the 90th Annual General Meeting of the Company and Scrutiniser''s report
BSE6/25/2026material
Intimation Under Regulation 30 Read With Schedule III Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Please find attached disclosure on ESG Rating.
BSE6/25/2026
Board Meeting Intimation for The Quarter Ended 30Th June, 2026 Under SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Cipla Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 23/07/2026 ,inter alia, to consider and approve the unaudited standalone and consolidated ....
BSE6/24/2026material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.